Drugs / NP001 cell injection
NP001 cell injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06671236 | Nov 2024 → Dec 2026 expected | amyotrophic lateral sclerosis | Novabio Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP001 Cell Injection | “Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)” NCT06671236 ↗ |
| Known as | Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection) | “Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)” NCT06671236 ↗ |
| Modality | Cell therapy | “NP001 cell injection are manufactured ex vivo to yield enriched Tregs.” NCT06671236 ↗ |
| Route | Intrathecal | “intrathecally on Days 1, 29, and 57” NCT06671236 ↗ |